Onvansertib

NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC50 of 2 nM.

Product Specifications

CAS Number

[1034616-18-6]

Product Name Alternative

NMS-1286937; NMS-P937

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Polo-like Kinase (PLK)

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/NMS-1286937.html

Purity

99.86

Solubility

DMSO : 21 mg/mL (ultrasonic; warming)

Smiles

O=C(C1=NN(CCO)C2=C1CCC3=CN=C(NC4=CC(N5CCN(C)CC5)=CC=C4OC(F)(F)F)N=C23)N

Molecular Formula

C24H27F3N8O3

Molecular Weight

532.52

Precautions

H302, H315, H319, H335

References & Citations

[1]Beria I, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21 (10) :2969-74.|[2]Valsasina B, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11 (4) :1006-16.|[3]Casolaro A, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8 (3) :e58424.